Russian Journal of Allergy最新文献

{"title":"Smoking and respiratory allergic diseases","authors":"E. A. Devyatkova, N. V. Minaeva, M. V. Tarasova","doi":"10.36691/rja1551","DOIUrl":"https://doi.org/10.36691/rja1551","url":null,"abstract":"The review presents a modern view on the problem of the impact of smoking on allergic respiratory diseases. Smoking is known to be a significant risk factor for asthma. Currently, it is of scientific interest to study the effect of smoking on allergic rhinitis and sensitization to allergens. Tobacco smoke affects the mucous membranes of the respiratory tract, contributing to a change in structure and dysfunction, and when exposed to allergens simultaneously, it can increase the activation of the Th2-immune response, increase the production of IgE, which may contribute to the development of allergic diseases. \u0000In recent years, e-cigarette smoking has become especially popular. The aerosol components of electronic cigarettes are characterized by irritant properties and inhalation toxicity. Smoking electronic cigarettes, like smoking traditional cigarettes, can affect the immunity of the respiratory mucosa, including the functions of epithelial cells, macrophages and neutrophils. \u0000The article presents conflicting data on the effect of smoking on sensitization to allergens. Tobacco smoke is a known trigger and exposure to it increases the risk of developing new cases of asthma in patients with allergic rhinitis. The influence of smoking on the development and clinical course of allergic pathology requires further study.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122350886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Drug-induced urticaria and angioedema","authors":"I. Vorzheva, Boris Anatolievich Chernyak","doi":"10.36691/rja1557","DOIUrl":"https://doi.org/10.36691/rja1557","url":null,"abstract":"The lecture presents drug-induced urticaria and angioedema: etiology, pathogenesis, clinic, diagnosis, differential diagnosis, principles of therapy and prevention","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"29 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133035424","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ceftriaxone Induced fixed drug eruption in patient with common variable immunodeficiency","authors":"Alina Shubina, T. Myasnikova, E. Frolov, V. Smirnov, E. Latysheva","doi":"10.36691/rja1563","DOIUrl":"https://doi.org/10.36691/rja1563","url":null,"abstract":"Adverse drug reactions are one of the most complex and difficult diagnostic problems in practice of allergists and clinical immunologists. This article presents a clinical case of a patient with inborn error of immunity, known as common variable immune deficiency with the debut of the disease in adulthood and the presence of numerous infectious, structural, and immune complications. The patient had an adverse drug reaction representive by fixed drug eruption to the vital antibiotic therapy with ceftriaxone. We provide detailed information about this type of drug allergy, structural features of cephalosporins and their cross-reactivity. In the diagnostic process, we ran phased drug allergy testing: patch tests and a dose provocative test, wich is considered as a gold standard for this type of diagnostics. According to the test results the diagnosis of fixed drug eruption to ceftriaxone and the absence of cross-reactivity to other cephalosporins in this patient was confirmed. The compiled individual recommendations made it possible to prohibit the use of only one drug (ceftriaxone), which is especially important for a patient with primary immunodeficiency.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126299045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Allergy in Russia today: problems and solutions","authors":"N. Ilyna","doi":"10.36691/rja1566","DOIUrl":"https://doi.org/10.36691/rja1566","url":null,"abstract":"The prevalence of allergic diseases worldwide is increasing dramatically in both developed and developing countries. Thus, according to the World Health Organization (WHO), allergic diseases affect up to 35% of the world's population. Allergopathology ranked 4th in terms of prevalence among all non-communicable diseases. In parallel, the severity of allergies is growing. According to experts from the World Allergy Organization (WAO), polyvalent sensitization is becoming more common, and allergies are becoming multi-organ.Due to ongoing air pollution and global warming, it is projected that up to half of Europe's population could suffer from allergic diseases by 2025.Allergic diseases not only affect the quality of life of patients and their loved ones, but also negatively affect the socio-economic well-being of society. Therefore, today allergic diseases should be considered as a global health problem.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133501575","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Soy: allergenic properties of proteins and IgE cross-reactions","authors":"V. B. Gervazieva, P. Samoylikov, E. M. Zaitsev, A. Bykov","doi":"10.36691/rja1558","DOIUrl":"https://doi.org/10.36691/rja1558","url":null,"abstract":"Since the last century, European countries began to actively use soybean seeds as food additives or for the production of food products with 100% replacement of milk and animal proteins with soy. In Russia, soy is a relatively new agricultural crop, which recently began to be used in food production. Meanwhile, it is known that some proteins of soybeans have the pronounced allergenic properties. 8 soy proteins (Gly m 1 - Gly m 8) are classified by the World Health Organization as allergens capable of causing clinically significant IgE-mediated sensitization in patients with allergic diseases. Moreover, most of these allergens have been included in the WHO nomenclature over the past 15 years. In addition, there is scientific evidence for the presence of other soybean allergens that can bind to sIgE. It has also been shown that some soy allergens have homology in amino acid sequence and three-dimensional similarity to proteins of other plants and animals. In this regard, questions of IgE - cross-reactivity are becoming relevant. In this way, the purpose of this review is to analyze and summarize scientific data on the chemical structure, properties, allergenic activity of soy and soybean proteins (soybean seeds), their cross-reactions with proteins of animal and plant origin.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130615078","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Suppression spontaneous and induced expression of CD203c basophils after \u0000subcutaneous immunotherapy with ragweed and mugwort allergens","authors":"Liudmila Yu. Barycheva, L. V. Dushina, S. S. Masalskiy, Y. S. Smolkin, Natalia A. Kozmova, Elena A. Kuropatnikova","doi":"10.36691/rja1534","DOIUrl":"https://doi.org/10.36691/rja1534","url":null,"abstract":"BACKGROUND: The basophil activation test (BAT) reflects the presence of IgE on the cell surface and can be a tool for monitoring the effectiveness of allergen-specific immunotherapy (ASIT). It is likely that spontaneous and allergen-induced BAT levels may change after effective subcutaneous immunotherapy (SCIT) and this is of clinical importance. \u0000AIMS: determination of basophil activation markers in patients sensitized to weed pollen during SCIT. \u0000MATERIALS AND METHODS: A real clinical study (2 years, 60 patients) with allergic rhinitis who underwent SCIT with weed allergens for 2 seasons. The proportion of basophils expressing CD203c spontaneously and after exposure to a trigger allergen was determined. BAT was performed before treatment, after the first and second courses of pre-season SCIT (0, 3, 15 months of treatment). The effectiveness of SCIT was assessed by the dynamics of the symptom scale (Rhinoconjunctivitis total symptom score) and the drug assessment (Daily medical score). \u0000RESULTS: SCIT with water-salt extracts was effective: median RTSS in patients after two courses decreased from 13.0 [10.0; 15.0] to 4.5 [3.00; 7.25] points (p 0.001), DMS score from 2.0 [2.0; 2.0] vs 1.0 [1.0; 2.0] points (p0.001). \u0000Spontaneous BAT remained unchanged after the first course of ASIT. Mean BAT values ​​before therapy and after the first course of SCIT did not differ (8.15 [6.10; 11.9] vs 9.0 [6.30; 12.0] %). After the second course of treatment, spontaneous BAT decreased (8.15 [6.10; 11.9] vs 6.20 [4.27; 9.00] %, 2 = 15.5, p0.001). \u0000Allergen-induced BAT decreased significantly from the first year of treatment. The overall change in the total group for BAT with ragweed after the first course of SCIT was 11.25 (CI 95 %: 7.10; 15.10) %, p 0.001. The overall difference in the induced ВAT test at the end of therapy reached 8.63 (CI 95: 5.30; 12.05) %, p 0.001. After the first course of therapy with mugwort allergens, the indices of induced BAT decreased by 12.0 (CI 95 %: 6.95; 17.90) %, p 0.001; after the second course, the difference from the initial values ​​was 9.67 (CI 95%: -6.85; 15.90) %, p0.001. \u0000CONCLUSIONS: SCIT with ragweed and mugwort allergens was effective. The change in spontaneous and induced BAT is associated with a positive effect of ASIT.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"54 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124161162","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"STUDY OF THE SILVER BIRCHPOLLEN ALLERGOID","authors":"Olga S. Kulaga, G. E. Avoyan, D. R. Esaulova, I. V. Andreev, K.O. Nechay, A. I. Andreev, Karina B. Kicheeva, O. S. Baklakova, O. V. Mislavsky, Vladimir I. Gegechkori, N. Cherchenko, M. N. Sankov, Аndrey Yu. Toptygin, S. M. Shvets, Tatiana S. Romanova, E. Latysheva, А. Martynov, M. Khaitov","doi":"10.36691/rja1549","DOIUrl":"https://doi.org/10.36691/rja1549","url":null,"abstract":"Background. Birch pollen is one of the main allergens in central Russia, Europe, North America, and in several other regions. Allergens contained in birch pollen often cause IgE cross-reactivity with homologous proteins both in other trees and in various foods. \u0000Allergen immunotherapy (AIT) is currently the only allergy treating method that directly affects various links in the pathogenesis of the disease, changing the body's response to the action of the allergen. The clinical effectiveness of ASIT reaches 8090% and is expressed by results in a decrease in clinical manifestations and the need for drugs. An allergoid, unlike an allergen, retains its immunogenicity, but significantly loses its allergenicity, which is makes it safer for use in with AIT. \u0000Aim. Obtaining an allergoid from the pollen of silver birch (lat. Btula pndula), by processing it with glutaraldehyde. \u0000Materials and Methods. The purified allergen isolated from pollen by degreasing and water-salt extraction was dissolved in PBS pH 7.5 and polymerized in 0.1% glutaraldehyde solution. Stabilization was carried out with a solution of sodium borohydride. \u0000Results. After assessing the specific activity using a competitive enzyme-linked immunosorbent assay (ELISA), it was seen that the allergoid significantly reduced its allergenicity compared to the original allergen. \u0000Conclusions. In the course of the work, an allergen of the silver birch was obtained. The resulting allergen contains major and minor antigens of silver birch (Bet v 1, Bet v 2, Bet v 3, Bet v 6, Bet v 7). On its basis, an allergoid was obtained by polymerization with glutaraldehyde. The resulting allergoid has a large molecular weight, and also has a low allergenic activity, in comparison with the original allergen. Thereby, this allergoid can become the basis for obtaining new AIT preparations.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"14 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133049840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The effectiveness of anti-IgE therapy for allergic rhinitis in patients with severe atopic bronchial asthma and concomitant allergic rhinitis in real clinical practice","authors":"D. Kiseleva, Evgeny K. Beltyukov, V. Naumova","doi":"10.36691/rja1533","DOIUrl":"https://doi.org/10.36691/rja1533","url":null,"abstract":"BACKGROUND: Omalizumab, by binding IgE in atopic patients, can improve clinical and functional parameters and patients' quality of life. \u0000AIMS: to evaluate efficacy of anti-IgE-therapy in patients with allergic rhinitis treated with omalizumab for concomitant severe atopic asthma in real clinical practice. \u0000MATERIALS AND METHODS: An open, non-interventional, prospective and non-randomized study in a real clinical practice. \u0000The study was conducted in the Sverdlovsk region in October 2021 based on a regional registry of adult patients with severe asthma with chronic nasal inflammatory diseases and receiving targeted therapy. Dynamics of nasal symptoms was assessed using SNOT-22 questionnaire and visual analogue scale initially, after 4 and 12 months of omalizumab therapy. Peripheral blood eosinophils level was also assessed before and after 4 months of omalizumab therapy. \u0000RESULTS: The study included 26 patients. Assessment of nasal symptoms dynamics using the SNOT22 questionnaire at baseline and after 4 months on omalizumab therapy revealed decrease in the severity of symptoms (p 0.001): baseline - 46.8522.04 points (95% CI 37.94-55.75), after 4 months - 30.6514.81 points (95% CI 24.67-36.64). Also improvement in SNOT22 questionnaire score was revealed in 18 patients treated with omalizumab during 12 month: before therapy - 47.5 points (Q₁ -Q₃: 35.7-59.3), after 4 months - 30.4 points (Q₁- Q₃: 22.1-38.1), after 12 months - 24.9 points (Q₁ -Q₃: 16.9-32.9) (p = 0.001). Improvement in rhinitis symptoms control was observed according to the VAS scale: VAS before therapy - 8.0 points (Q₁-Q₃: 6.2-9.0), after 4 months - 5.0 points (Q₁- Q₃: 3.2-5, 8), after 12 months of treatment - 5.0 points (Q₁-Q₃: 4.0-6.8). The level of eosinophils (n=16) decreased from 510.9317.9 (95% CI 341.5680.3) cells /l to 327.4217.7 (95% CI 211.4443.5) cells /l after 4 months of anti-IgE-therapy (p0.041). \u0000CONCLUSIONS: Omalizumab in real clinical practice has demonstrated improvement of rhinitis symptoms control and quality of life in patients with allergic rhinitis with concomitant severe atopic asthma. It was accompanied by a statistically significant decrease in peripheral blood eosinophils level, that largely determines airway inflammation severity and clinical manifestations of allergic rhinitis and bronchial asthma.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133420189","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resolution of the Working Meeting of Experts in Dermatology: \"Possibilities of systemic therapy of atopic dermatitis with selective immunosuppressants\"","authors":"Л. Бакулев, А. Вишнева, О. Г. Елисютина, Н. И. Ильина, А. Э. Карамова, М. М. Кохан, Арсений Александрович Кубанов, К. Н. Монахов, Л. С. Намазова, Баранова, Г. А. Новик, О Ю Олисова, В. А. Ревякина, Е. В. Соколовский, Е. С. Феденко, М. М. Хобейш, Российская Федерация","doi":"10.36691/rja1546","DOIUrl":"https://doi.org/10.36691/rja1546","url":null,"abstract":"On February 19, 2022, a working meeting of experts on the problem of atopic dermatitis was held in Moscow under the chairmanship of the Director of the State Scientific Center for Dermatovenereology and Cosmetology of the Ministry of Health of Russia, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences A.A. Kubanov, Academician of the Russian Academy of Sciences, Chief Freelance Children's Specialist in Preventive Medicine, Head of the Research Institute of Pediatrics and Children's Health of the Central Clinical Hospital of the Russian Academy of Sciences of the Ministry of Science and Higher Education of the Russian Federation, Doctor of Medical Sciences, Professor, Academician of the Russian Academy of Sciences L.S. Namazova-Baranova, Deputy Director for Clinical Work - Chief Physician of the Federal State Budgetary Institution \"SSC\" Institute of Immunology \"FMBA of Russia\" Doctor of Medical Sciences, Professor N.I. Ilyina. \u0000The meeting raised topical issues of providing medical care, reducing the burden of the disease and improving the quality of life of patients with atopic dermatitis (AD). New possibilities and principles of systemic therapy in patients with moderate and severe AD were discussed. We analyzed data on a new representative of the small molecule class, the selective Janus kinase 1 inhibitor, upadacitinib, which was registered in the Russian Federation in June 2021, in order to determine its place in AD therapy algorithms and the possibility of the impact of therapy with its use on the quality of life of patients and the burden of diseases.","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115594322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence and risk factors for food allergy in children: a review of epidemiological studies","authors":"V. Prokopyeva, M. M. Fedotova, U. V. Konovalova, V. A. Dochkin, O. Fedorova","doi":"10.36691/rja1531","DOIUrl":"https://doi.org/10.36691/rja1531","url":null,"abstract":"Relevance. Food allergy (FA) is an actual problem in pediatric practice. In recent decades, there has been an increase in the prevalence and an increase in the number of severe cases of FA. \u0000Purpose: to analyze epidemiological cohort and cross-sectional studies aimed at studying the prevalence and risk factors for FA in children \u0000Materials and methods. A systematic review of epidemiological cohort and cross-sectional studies studying the developmental factors and prevalence of FA, published in the period January 1, 2000 - December 31, 2021, was carried out. \u0000Results. The review made it possible to generalize and systematize the accumulated worldwide scientific data on FA. An analysis of epidemiological studies has demonstrated a significant prevalence of FA and reflected the patterns of its natural course: the highest rates were noted among young children, and by school age, the prevalence of symptoms and confirmed FA is gradually decreasing. Based on epidemiological data, the main risk factors for FA are hereditary predisposition and environmental factors that modify the microbial environment. \u0000Conclusion. It is necessary to further study the genetic markers of FA and study the role of microbiotic factors in the implementation of hereditary predisposition to allergic diseases. \u0000Keywords: Food allergy, prevalence, risk factors, children","PeriodicalId":270411,"journal":{"name":"Russian Journal of Allergy","volume":"201 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115714955","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}